Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vicriviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.84 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vicriviroc SCHEMBL118885 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL4638191 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL4447817 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL29392831 | 0.96 | CCR5 (0.91) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL19656878 | 0.95 | CCR5 (0.91) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL3321008 | 0.95 | CCR5 (0.90) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14032029 | 0.92 | CCR5 (0.85) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13484306 | 0.92 | CCR5 (0.84) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL15199622 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL10073358 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12228580-B2 | Methods of assigning a COVID pathological type based on a cytokine/chemokine panel | INCELLDX, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-11952373-B2 | Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc | INCELLDX, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240019447-A1 | Methods of Assigning a COVID Pathological Type and Compositions for Practicing the Same, and Methods of Treating a Subject for Chronic COVID-19 | INCELLDX, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230364085-A1 | USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS | PESTELL RICHARD G (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4264280-A1 | METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE AND COMPOSITIONS FOR PRACTICING THE SAME, AND METHODS OF TREATING A SUBJECT FOR CHRONIC COVID-19 | IncellDx, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11633397-B2 | Use of modulators of CCR5 in the treatment of cancer and cancer metastasis | PESTELL RICHARD G (US) | 2023-04-25 | — | — | US | disclosed |
| US-11629196-B2 | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions | INCELLDX, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115414480-A | Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme | 德玛医药 | 2022-12-02 | — | — | CN | disclosed |
| US-20220317134-A1 | Methods of Assigning a COVID Pathological Type and Compositions for Practicing the Same, and Methods of Treating a Subject for Chronic COVID-19 | INCELLDX, INC. | 2022-10-06 | — | — | US | disclosed |
| US-10301281-B2 | Crystal forms of a CCR5 antagonist | MERCK SHARP & DOHME CORP. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3463373-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | Akarna Therapeutics, Ltd. (GB) | 2019-04-10 | — | — | EP | disclosed |
| US-20180303830-A1 | CANCERS EXPRESSING CCR5 AND METHODS OF TREATMENT OF SAME | THOMAS JEFFERSON UNIVERSITY (US) | 2018-10-25 | — | — | US | disclosed |
| US-20170342053-A1 | CRYSTAL FORMS OF A CCR5 ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2017205684-A1 | COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS | AKARNA THERAPEUTICS, LTD. (GB) | 2017-11-30 | — | — | WO | disclosed |
| US-20170342053-A1 | CRYSTAL FORMS OF A CCR5 ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170231991-A1 | Use Of Modulators Of CCR5 In The Treatment Of Cancer And Cancer Metastasis | NIH-DEITR | 2017-08-17 | — | — | US | disclosed |
| WO-2016209926-A1 | CANCERS EXPRESSING CCR5 AND METHODS OF TREATMENT OF SAME | THOMAS JEFFERSON UNIVERSITY (US) | 2016-12-29 | — | — | WO | disclosed |
| US-9453836-B2 | Use of modulators of CCR5 in the treatment of cancer and cancer metastasis | PESTELL, RICHARD G. | 2016-09-27 | — | — | US | disclosed |
| US-20130303512-A1 | Use of modulators of CCR5 in the treatment of Cancer and cancer metastasis | PESTELL, RICHARD G. | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342053-A1 | CRYSTAL FORMS OF A CCR5 ANTAGONIST | CCR5, CCL5, CCR2 | CCR5 1/4885CHRM2 421/4885CHRM1 207/4885 |
| US-10301281-B2 | Crystal forms of a CCR5 antagonist | CCR5, CCL5, CCR2 | CCR5 1/4885CHRM2 421/4885CHRM1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.